Malignant melanoma Antibody
Malignant melanoma Antibody
 Primary malignant melanoma |
|||
| ME204 | TissueArray | each | 534 EUR |
|
Description: Primary malignant melanoma, metastatic malignant melanoma and skin tissue array, incluing TNM /Stage, 68 cases/204 cores (core size 1.0mm),replacing ME208 |
|||
 Malignant melanoma tissue array |
|||
| ME1005a | TissueArray | each | 414 EUR |
|
Description: Malignant melanoma tissue array, including TNM and clinical stage, 50cases/ 100 cores, replacing ME1005 |
|||
Malignant melanoma tissue array |
|||
| ME483a | TissueArray | each | 270 EUR |
|
Description: Malignant melanoma tissue array, including TNM and clinical stage, 48 cases/48 cores, replacing ME483 |
|||
Malignant melanoma tissue array |
|||
| ME804a | TissueArray | each | 348 EUR |
|
Description: Malignant melanoma tissue array, including TNM, clinical stage and pathology grade, 80 cases/80 cores, replaced by ME804b |
|||
Malignant melanoma tissue array |
|||
| ME804b | TissueArray | each | 348 EUR |
|
Description: Malignant melanoma tissue array, including TNM, clinical stage and pathology grade, 80 cases/80 cores, replacing ME804a |
|||
Malignant melanoma tissue array |
|||
| T386a | TissueArray | each | 66 EUR |
|
Description: Malignant melanoma tissue array, with normal skin tissue, including TNM and clinical stage, 6 cases/24 cores, replacing T386 |
|||
Malignant melanoma tissue array |
|||
| T388b | TissueArray | each | 66 EUR |
|
Description: Malignant melanoma tissue array, including TNm and clinical stage, 6 cases/24 cores, replacing T388a |
|||
 Mucosa malignant melanoma tissue array |
|||
| BCC38018 | TissueArray | each | 270 EUR |
|
Description: Mucosa malignant melanoma tissue array, 40 cases/80 cores |
|||
 Metastatic malignant melanoma tissue array |
|||
| BCC38218 | TissueArray | each | 270 EUR |
|
Description: Metastatic malignant melanoma tissue array, 50 cases/100 cores |
|||
 Malignant melanoma test tissue array |
|||
| T385b | TissueArray | each | 66 EUR |
|
Description: Malignant melanoma test tissue array, including TNM and clinical stage, 6 cases/24 cores, replacing T385a |
|||
 Malignant melanoma and metastatic malignant melanoma TMA with 6 matched cancer adjacent tissue samples |
|||
| ME551 | TissueArray | each | 270 EUR |
|
Description: Malignant melanoma and metastatic malignant melanoma TMA with 6 matched cancer adjacent tissue samples, including TNM and clinical stage (reference AJCC th version), 49cases/55 cores (core size 1.5mm) Recent Year Collection |
|||
 Malignant melanoma with skin tissue array |
|||
| ME1002b | TissueArray | each | 348 EUR |
|
Description: Malignant melanoma with skin tissue array, including TNM and clinical satge, 50 cases/100 cores, replacing ME1002a |
|||
Malignant melanoma with skin tissue array |
|||
| ME2082d | TissueArray | each | 546 EUR |
|
Description: Malignant melanoma with skin tissue array, including TNM and clinical stage, 188 cases/192 cores(1.0mm), replacing ME2082c |
|||
Malignant melanoma with skin tissue array |
|||
| ME242c | TissueArray | each | 108 EUR |
|
Description: Malignant melanoma with skin tissue array, including TNM and clinical stage, 24 cases/24 cores, replacing ME242b |
|||
Malignant melanoma with skin tissue array |
|||
| ME803b | TissueArray | each | 306 EUR |
|
Description: Malignant melanoma with skin tissue array, including TNM and clinical stage, 80 cases/80 cores (core size 1.5mm), replacing ME803a |
|||
 Malignant melanoma and benign nevus tissue array |
|||
| SK181 | TissueArray | each | 174 EUR |
|
Description: Malignant melanoma and benign nevus tissue array, including TNM and clinical stage, 18 cases/18 cores |
|||
 Malignant melanoma with skin tissue test array |
|||
| T383a | TissueArray | each | 66 EUR |
|
Description: Malignant melanoma with skin tissue test array, including TNM and clinical stage, 6 cases/24 cores, replacing T383 |
|||
 Paraffin Tissue Section - Human Skin Tumor: Malignant Melanoma |
|||
| T2235218-3 | Biochain | 5 slides | 308.4 EUR |
|
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
|||
 Malignant melanoma test tissue array with skin tissue |
|||
| T382c | TissueArray | each | 66 EUR |
|
Description: Malignant melanoma test tissue array with skin tissue, including pathology grade, TNM and clinical stage, 12 cases/24 cores, replacing T382b |
|||
 Multiple sites malignant melanoma and normal skin tissue array |
|||
| ME2081 | TissueArray | each | 474 EUR |
|
Description: Multiple sites malignant melanoma and normal skin tissue array, including TNM and clinical stage, 104 cases/208 cores (core size 1.5mm) |
|||
 (5 slides/pack)) Human Malignant melanoma (single section per slide) (5 slides/pack) |
|||
| HuCAT576 | TissueArray | 5 slides | 180 EUR |
 Multiple malignant melanoma tissue array with adjacent normal skin tissue |
|||
| ME241b | TissueArray | each | 66 EUR |
|
Description: Multiple malignant melanoma tissue array with adjacent normal skin tissue, including TNM and clinical stage, 12 cases/24 cores, replacing ME241a |
|||
 Skin malignant melanoma tissue array with adjacent skin tissue as control |
|||
| ME811 | TissueArray | each | 270 EUR |
|
Description: Skin malignant melanoma tissue array with adjacent skin tissue as control, including TNM, clinical stage, 42 cases/ 81 cores |
|||
 Skin malignant melanoma tissue array with adjacent normal or normal skin tissue as control |
|||
| ME482a | TissueArray | each | 270 EUR |
|
Description: Skin malignant melanoma tissue array with adjacent normal or normal skin tissue as control, 48 cases/ 48 cores, replacing ME482 |
|||
) Penis Tissue Slide (Malignant) |
|||
| 12-204-10um | ProSci | 10 um | 241.8 EUR |
Penis Tissue Slide (Malignant) |
|||
| 12-204-4um | ProSci | 4 um | 216.6 EUR |
 Malignant fibrohistiocytoma tissue array |
|||
| SO802 | TissueArray | each | 270 EUR |
|
Description: Malignant fibrohistiocytoma tissue array, 80 cases/80 cores |
|||
 Melanoma Antibody / PNL2 |
|||
| V3071-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
|||
Melanoma Antibody / PNL2 |
|||
| V3071-20UG | NSJ Bioreagents | 20 ug | 219 EUR |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
|||
Melanoma Antibody / PNL2 |
|||
| V3071IHC-7ML | NSJ Bioreagents | 7 ml | 499 EUR |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
|||
Melanoma Antibody / PNL2 |
|||
| V3071SAF-100UG | NSJ Bioreagents | 100 ug | 499 EUR |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
|||
) Melanoma Tissue Slide (Skin- Melanoma) |
|||
| 12-801-10um | ProSci | 10 um | 241.8 EUR |
Melanoma Tissue Slide (Skin- Melanoma) |
|||
| 12-801-4um | ProSci | 4 um | 216.6 EUR |
) Liver Tissue Slide (Malignant tumor) |
|||
| 10-220-10um | ProSci | 10 um | 241.8 EUR |
Liver Tissue Slide (Malignant tumor) |
|||
| 10-220-4um | ProSci | 4 um | 216.6 EUR |
) Stomach Tissue Slide (Malignant Tumor) |
|||
| 10-807-10um | ProSci | 10 um | 241.8 EUR |
Stomach Tissue Slide (Malignant Tumor) |
|||
| 10-807-4um | ProSci | 4 um | 216.6 EUR |
) Small Intestine Tissue Slide (Malignant) |
|||
| 11-814-10um | ProSci | 10 um | 241.8 EUR |
Small Intestine Tissue Slide (Malignant) |
|||
| 11-814-4um | ProSci | 4 um | 216.6 EUR |
) Ovary Tissue Slide (Malignant Tumor) |
|||
| 11-206-10um | ProSci | 10 um | 241.8 EUR |
Ovary Tissue Slide (Malignant Tumor) |
|||
| 11-206-4um | ProSci | 4 um | 216.6 EUR |
Stomach Tissue Slide (Malignant Tumor) |
|||
| RF10002-05-10um | ProSci | 10 um | 241.8 EUR |
Stomach Tissue Slide (Malignant Tumor) |
|||
| RF10002-05-4um | ProSci | 4 um | 216.6 EUR |
 Skin malignant tumor tissue array |
|||
| BC21014 | TissueArray | each | 270 EUR |
|
Description: Skin malignant tumor tissue array, 78 cases/78 cores, replacing BC21011 |
|||
 Melanoma associated antigen antibody |
|||
| 10R-M160a | Fitzgerald | 1 mL | 626.4 EUR |
|
Description: Mouse monoclonal Melanoma associated antigen antibody |
|||
 Antibody) Melanoma Marker(PNL2) Antibody |
|||
| BNC040894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC040894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405S conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC050894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC050894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
|||
 Melanoma Inhibitory Activity Antibody |
|||
| DF14235 | Affbiotech | 100ul | 420 EUR |
Melanoma Marker(PNL2) Antibody |
|||
| BNCAP0894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCAP0894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCB0894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCB0894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Biotin conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCP0894-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCR0894-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC940894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC940894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF594 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCA0894-250 | Biotium | 250uL | 459.6 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC810894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC810894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNUB0894-100 | Biotium | 100uL | 250.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNUB0894-500 | Biotium | 500uL | 549.6 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Concentration: 0.2mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCH0894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNCH0894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC880894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC880894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF488A conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC680894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC680894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF568 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC470894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC470894-500 | Biotium | 500uL | 652.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF647 conjugate, Concentration: 0.1mg/mL |
|||
Melanoma Marker(PNL2) Antibody |
|||
| BNC400894-100 | Biotium | 100uL | 238.8 EUR |
|
Description: Primary antibody against Melanoma Marker(PNL2), CF640R conjugate, Concentration: 0.1mg/mL |
|||